AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease.

Abstract

There is an urgent need for Alzheimer's disease (AD) biomarkers-especially in the context of clinical trials. Biomarkers for early diagnosis, disease progression, and prediction are most critical, and disease-modification therapy development may depend on the discovery and validation of such markers. AddNeuroMed is a cross European, public/private… (More)
DOI: 10.1111/j.1749-6632.2009.05064.x

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.